Kai ƙwararren ma'aikacin kiwon lafiya ne?

Wannan shafin yana ƙunshe da bayanan asibiti da aka nufa ƙwararrun ma'aikatan kiwon lafiya. Ta hanyar ci gaba, kun tabbatar da cewa kai ƙwararren likita ne.

A'a, kai ni baya

Ga likitoci masu ba da shawara

Ku ne mai yanke shawara ga majinyacinku. Wannan shafi yana ba ku abin da kuke buƙatar tsayawa a bayan ba da shawara a hanyar ƙwararru.

"In na aika majinyacina, zan iya tsayawa a bayansa a hanyar ƙwararru?"

Ma'aunin cancantar

Ma'aunin zaɓin majinyaci mai haske, da aka duba kowane yanayi — don ku san kafin ba da shawara ko majinyacinku ya dace da shirin.

Bayanan samfurin da na alama

Antigens na alama (CD19/CD22 alama biyu, BCMA), tsarin samarwa da tsarin inganci — an raba cikin cikakken bayani.

Tsare-tsaren CRS da ICANS

Tsare-tsaren matakai da sarrafawa don cutar cytokine da cutar kwakwalwa, daidaitawa da cibiyar magani.

Yiwuwar conditioning

Inda ya dace da asibiti, za a iya ba da conditioning a ƙasarsu — rage zama a Türkiye.

Tuntuɓar mutum ɗaya

Ɗayan mai haɗin gwiwa don duka hanyar — daga ba da shawara zuwa dawo da bayanan. Babu cibiyoyin kira, babu bayarwa.

Bayanan da kuke karɓa

Lokacin da majinyacinku ya dawo, kuna karɓar bayanan bin diddigin da aka tsara a tsarin da za ku iya amfani da shi — ci gaba da kulawa da fara ku.

Fakitin bayanan likita

Rajista tana ba ku damar isa ga cikakken bayanan nazarin da ke bayan waɗannan shirye-shirye — tunanin da aka buga, bayanan mataki, da bayanan aminci — don tantancewa da kanku.

Nemi fakitin bayanan likita

Shaida

Bugudun nazarin 36 bayan waɗannan shirye-shirye

Gwaje-gwaje na asibiti, rahotannin lokuta da nazarin ƙwararru suna tallafawa shirye-shiryen maganar CAR-T na Hillgene CD19/CD22, Hillgene BCMA da UniCar — duk suna da hanyoyin PubMed.

CD19/CD22 — 11 BCMA — 6 CD19 — 19
Duba duk bugudun nazarin

Hanyar Samarwa

Hanyar Samfur

Samfuran CAR-T na farko a irinsu daga abokin haɗinmu UniCar (Shanghai Ucardi Biomedical Technology) a cikin matakin binciken asibiti da aka yi rajista.

Binciken Asibiti Mai Mahimmanci CD20

Allurar U16 (CD20 CAR-T)

Maganin lymphoma maras CD19. Bayanan ASH 2024: 100% ORR, 68.75% na darajar CR a cikin R/R B-NHL da ba a iya magance shi da rituximab. PFS tsakiya watanni 14.5 tare da ingantaccen aminci (babu darajar CRS na mataki 4).

NHL na ƙwayoyin B Rituximab-ƙin yarda Koma bayan/Kin amsawa
Binciken Asibiti Mai Mahimmanci CD19 + IL-6 KD

Allurar ssCART-19 (Cutar Binta ta CNS)

Anti-CD19 CAR-T tare da shirye-shiryen IL-6 don cutar B-cell ALL ta CNS — wanda a baya ya kasance ba a yarda da CAR-T. An ba da sunan magani na FDA, kuma an ba da darajar maganin NMPA. Mataki na 1 ya nuna warware alamu gaba ɗaya tare da CRS na darajar 1 kawai.

B-ALL na CNS Ciwon sankarau na kwakwalwa Maganin cututtukan da ba sa yaduwa (FDA)
Mataki na I Ɗan Adam Cikakken

Allurar U87 (CAR-T Ɗan Adam Cikakken)

Samfurin CAR-T na ɗan adam cikakken da ke nufin ƙwayoyin cuta masu ƙarfi. Yana magance iyakantattun ƙwayoyin halitta na murine-derived CAR-T. A cikin mataki na I na binciken da aka yi rajista.

Ciwon huhu TNBC Ciwon ƙwaƙwalwa Nasofaringeal Kolorektal
Bincike CD19+ TAET

Ƙwayoyin T da ke Bayyana Antigen (TAET)

Sabuwar dabara don inganta aikin CAR-T a cikin yanayin ƙarancin ƙwayoyin cuta. Ƙwayoyin CD19+ TAET suna sake kunna CAR-T lokacin da ƙwayoyin cuta masu rage sun faɗi ƙasa da iyaka, suna ba da damar share MRD sosai. An gabatar da bayanan ASH 2024.

Sharewa MRD Ƙarancin ɗaukar cuta Ƙara ƙarfin CAR-T

Ana raba bayanan likita ga likitoci masu rajista kawai, tare da tushe. Wannan shafi ba ya buga lambobin inganci.